Zogenix PR: Topline Ph3 FINTEPLA in LGS

February 7, 2020
Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome 

  • Primary Endpoint Achieved – Statistically Significant Reduction in Drop Seizures for FINTEPLA 0.7 mg/kg/day versus Placebo 
  • FINTEPLA Also Demonstrated Statistically Significant Improvement on Multiple Secondary Endpoints 
  • Zogenix to Host Conference Call and Live Webcast Today at 4:30 PM Eastern Time/1:30 PM Pacific Time 

EMERYVILLE, California, February 6, 2020 – Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution) in Lennox- Gastaut Syndrome (LGS), a severe and treatment-resistant childhood-onset epilepsy. The trial met its primary objective of demonstrating that FINTEPLA at a dose of 0.7 mg/kg/day was superior to placebo in reducing the frequency of drop seizures, based on the change between baseline and the titration and maintenance treatment period (p=0.0012). The same dose of FINTEPLA (0.7 mg/kg/day) also demonstrated statistically significant improvements versus placebo in key secondary efficacy measures, including the proportion of patients with a clinically meaningful reduction (≥50%) in drop seizure frequency. A decrease in the frequency of drop seizures between baseline and the treatment period was observed for a lower dose of FINTEPLA (0.2 mg/kg/day) compared to placebo, but this change did not reach statistical significance (p=0.0915). FINTEPLA was generally well- tolerated, with the adverse events consistent with those observed in the Company’s two prior Phase 3 studies in Dravet syndrome. 

“LGS is a rare and severe form of epilepsy where nearly all patients have highly treatment resistant and lifelong seizures. As a result, the frequent falls and injuries, and also the cognitive impairment, limit the quality of life for patients and caregivers, even with current treatment options,” said Associate Professor Kelly Knupp, M.D., MSCS, FAES of Children’s Hospital Colorado, Principal Investigator for Study 1601. “The results observed in this placebo- controlled study are indicative of the potential of fenfluramine to treat patients with refractory LGS. If approved, FINTEPLA could represent an important new treatment option for these patients and their families in need.” 

Read More

 

Related Posts

Medication Recall Alert Sabril® (Vigabatrin)

Medication Recall Alert Sabril® (Vigabatrin)

Our friends at the Epielpsy Foundation have shared the Following Medication Recall The company that makes Sabril® (vigabatrin) for oral solution, a prescription medication to manage seizures in children and adults, has announced a recall of this medication because of...

MEDICATION ALERT – FELBAMATE (Generic)

MEDICATION ALERT – FELBAMATE (Generic)

We understand that some families in our community may be having challenges getting prescriptions filled for generic Felbamate oral suspension and tablets. If you need assistance with obtaining your medication, contact our 24/7 Helpline at 1-800-332-1000 for connection...

Medicaid Eligibility Renewals are Coming!

Medicaid Eligibility Renewals are Coming!

Medicaid Eligibility Renewals are Coming! Medicaid eligibility renewals were paused during the COVID-19 pandemic but are re-starting soon. This means that almost everyone on Medicaid in the US will need to renew their eligibility at some point between February 2023...